Objectives: To assess first clinical experiences with brivaracetam (BRV) in the treatment of epilepsies.
Methods: Data on patients treated with BRV from February to December 2016 and with at least one clinical follow-up were collected from electronic patient records. Data on safety and efficacy were evaluated retrospectively.